Does salpingectomy prevent ovarian cancer? Let’s prove it. The SOROCk clinical trial, NRG CC008 (NCT04251052)

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

On May 21, staff members of NCI’s dissolved Office of Communications and Public Liaison and friends gathered at the house of Peter Garrett and Ken Crerar.

May 23, 2025

Vol.51 No.20

Cancer Policy

NCI Cancer Information Highlights bulletin cut due to RIFs

NCI’s Cancer Information Highlights bulletin, a section of NCI’s Weekly Digest Bulletin that informs readers of research updates related to cancer causes, prevention, screening, treatment, and coping, will no longer be published due to restructuring and reductions in force at HHS.

May 23, 2025

Vol.51 No.20

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.

May 23, 2025

Vol.51 No.20

Podcast The Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH.

May 16, 2025

Vol.51 No.19

By Jacquelyn Cobb

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

YOU MAY BE INTERESTED IN

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

NCI Cancer Information Highlights bulletin cut due to RIFs

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Renew today!

Subscriber content

Never miss an issue!

Login

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

YOU MAY BE INTERESTED IN

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

NCI Cancer Information Highlights bulletin cut due to RIFs

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”